Breaking News, Promotions & Moves

Executive Moves: Daiichi Sankyo Co.

Senior-level organizational changes will oversee the company's strategic priorities

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Daiichi Sankyo Co. has made senior-level organizational changes to oversee the company’s strategic priorities, which include delivering seven new molecular entities in oncology by 2025.   Junichi Koga, Ph.D. will become the new global head of R&D Unit, drawing from his deep expertise in bioengineering and biologics research and development. Dr. Koga, currently senior executive officer and head of the R&D Division in Japan, will assume his new role on April 1, 2019 and will reloc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters